Amgen (NASDAQ:AMGN) SVP Nancy Grygiel Sells 1,237 Shares

Amgen Inc. (NASDAQ:AMGN) SVP Nancy Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Amgen Stock Performance

Amgen stock traded up $5.74 during mid-day trading on Tuesday, reaching $329.59. 3,318,185 shares of the company’s stock were exchanged, compared to its average volume of 2,623,884. The business’s fifty day simple moving average is $357.16 and its 200 day simple moving average is $341.35. The firm has a market capitalization of $177.87 billion, a PE ratio of 22.94, a P/E/G ratio of 3.08 and a beta of 0.44. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.45 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Hedge Funds Weigh In On Amgen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. High Note Wealth LLC grew its position in Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares in the last quarter. TAGStone Capital Inc. grew its position in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after buying an additional 28 shares in the last quarter. Verus Capital Partners LLC grew its position in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after buying an additional 28 shares in the last quarter. Destination Wealth Management grew its position in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after buying an additional 29 shares in the last quarter. Finally, Breakwater Capital Group grew its position in Amgen by 1.4% during the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after buying an additional 29 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a “hold” rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMGN. Guggenheim decreased their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research report on Tuesday. Morgan Stanley set a $332.00 price target on Amgen in a research report on Friday. Finally, Rothschild & Co Redburn lifted their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $357.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.